FELE max pain, gamma exposure (GEX) & options open interest
As of close · rank #4427 by open interest · snapshot page
FELE's nearest-expiration max pain is 95.00 for 2026-10-16, net GEX is 166,570, its put/call open-interest ratio is 0.20. These are whole-chain derived aggregates as of Oct 2, 2026 close.
Whole-chain analytics
Derived after the close from the same dated options chain. Signed gamma exposure uses calls positive and puts negative; it is a model convention, not observed dealer inventory.
Advanced options analysis
Complete derived analysis from the dated chain, normalized where possible for comparison across tickers. Catalyst intensity measures unusual pricing and activity; it does not identify an event, predict direction, or establish that an investment is attractive.
Total open interest is 234, 0.0% versus the previous session. What gamma max means · What delta neutral means
History
Hover for valuesDrag to panScroll to zoomClick a series to hide it ← → step a session+ − zoomTouch: swipe to pan, pinch to zoom, hold for the crosshair
Analysis visualizations
Derived from the 2026-10-02 options chain. Select an analysis to explore its chart.
No matching visualizations.
Gamma walls
Chart loads when this section is in view.
In today's screens
Not in any screen today. See all screens.
Neighbours by open interest
Questions people ask about FELE
Where is FELE's gamma max today?
No gamma max could be computed for FELE on Oct 2, 2026. Gamma max is the underlying price at which the summed gamma of every open contract is largest; how it is computed and why it matters.
Is FELE above or below its delta neutral price?
No delta neutral price was available for FELE on Oct 2, 2026. The delta neutral price is where the summed delta of the whole chain is zero; the definition.
How much open interest does FELE have?
234 contracts of open interest across 11 listed contracts on Oct 2, 2026, 0.0% versus the previous session. What open interest measures.
Levels are recomputed after every trading day from licensed end-of-day options data; only derived aggregates are published. Methodology · Data and licence · Not investment advice.